Revance Therapeutics, Inc. has announced that the U.S. Centers for Medicare & Medicaid Services have granted DAXXIFY a permanent J-code. DAXXIFY is a treatment for cervical dystonia in adults. These unique J-codes indicate product-specific reimbursement by commercial insurance plans, Medicare, and other government entities.
Mark Foley, CEO of Revance, shared their progress: "We have obtained our reimbursement code and secured coverage for over 100 million commercially insured individuals from leading payers across the nation. We aim to introduce DAXXIFY to the therapeutic market by mid-year."
For more health-related news, please visit rttnews.com.
